bupropion hydrochloride
Drug Details
- Generic Name
- bupropion hydrochloride
- Brand Names
- Bupropion Hydrochloride SR, Bupropion Hydrochloride (XL), Bupropion Hydrochloride XL, bupropion hydrochloride, bupropion hydrochloride SR, BUPROPION HYDROCHLORIDE, bupropion, buPropion Hydrochloride XL, BuPROPion Hydrochloride, WELLBUTRIN SR
- Application Number
- ANDA079095
- Sponsor
- Actavis Pharma, Inc.
- NDC Codes
- 50
- Dosage Forms
- TABLET, FILM COATED, EXTENDED RELEASE, POWDER, TABLET, EXTENDED RELEASE, TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- BUPROPION HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD) ( 1.1 ) prevention of seasonal affective disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder (MDD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies (14.1) ]. 1.2 Seasonal Affective Disorder (SAD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). The efficacy of bupropion hydrochloride extended-release tablets (XL) in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in adult outpatients with a history of MDD with an autumn-winter seasonal pattern as defined in the DSM [see Clinical Studies (14.2) ].